Michael J LaBarre
Overview
Explore the profile of Michael J LaBarre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nolan R, Kang D, Maneval D, Knowles S, LaBarre M, Printz M
J Control Release
. 2024 Aug;
374:369-383.
PMID: 39089505
Hyaluronan (HA) is a glycosaminoglycan that forms a gel-like barrier in the subcutaneous (SC) space, limiting bulk fluid flow and the dispersion of SC-administered therapeutics. Recombinant human hyaluronidase PH20 (rHuPH20)...
2.
Printz M, Sugarman B, Paladini R, Jorge M, Wang Y, Kang D, et al.
AAPS J
. 2022 Oct;
24(6):110.
PMID: 36266598
Multiple FDA-approved and clinical-development stage therapeutics include recombinant human hyaluronidase PH20 (rHuPH20) to facilitate subcutaneous administration. As rHuPH20-reactive antibodies potentially interact with endogenous PH20, we investigated rHuPH20 immunogenicity risk through...
3.
Knowles S, Printz M, Kang D, LaBarre M, Tannenbaum R
Expert Opin Drug Deliv
. 2021 Sep;
18(11):1673-1685.
PMID: 34585991
Introduction: The glycosaminoglycan hyaluronan forms a gel-like substance, which presents a barrier to bulk fluid flow in the subcutaneous (SC) space, limiting SC drug delivery volume and administration rates. Recombinant...
4.
Wang L, Londono L, Cowell J, Saatci O, Aras M, Ersan P, et al.
Cancer Res
. 2021 Apr;
81(12):3319-3332.
PMID: 33863778
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can...
5.
Badkar A, Gandhi R, Davis S, LaBarre M
Drug Des Devel Ther
. 2021 Jan;
15:159-170.
PMID: 33469268
Subcutaneous (SC) delivery of biologics has traditionally been limited to fluid volumes of 1-2 mL, with recent increases to volumes of about 3 mL. This injection volume limitation poses challenges...
6.
Connor R, Taverna D, Thrall K, LaBarre M, Kang D
J Pharmacol Toxicol Methods
. 2020 Nov;
106:106936.
PMID: 33191187
Introduction: Subcutaneous (SC) formulations of therapeutics with recombinant human hyaluronidase PH20 (rHuPH20) are currently approved across various disease indications. The rHuPH20-mediated enzymatic degradation of SC hyaluronan (HA) facilitates bulk fluid...
7.
Locke K, Maneval D, LaBarre M
Drug Deliv
. 2019 Feb;
26(1):98-106.
PMID: 30744432
ENHANZE drug delivery technology is based on the proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20; Halozyme Therapeutics, Inc.) that facilitates the subcutaneous (SC) delivery of co-administered therapeutics. rHuPH20 works by...
8.
Li X, Shepard H, Cowell J, Zhao C, Osgood R, Rosengren S, et al.
Clin Cancer Res
. 2018 Aug;
24(19):4798-4807.
PMID: 30084839
The tumor microenvironment (TME) evolves to support tumor progression. One marker of more aggressive malignancy is hyaluronan (HA) accumulation. Here, we characterize biological and physical changes associated with HA-accumulating (HA-high)...
9.
Fang S, Hays Putnam A, LaBarre M
Anal Biochem
. 2015 Apr;
480:74-81.
PMID: 25866075
The kinetic investigation of hyaluronidases using physiologically relevant hyaluronic acid (HA or hyaluronan) substrate will provide useful and important clues to their catalytic behavior and function in vivo. We present...
10.
Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, Arnon T, et al.
J Clin Invest
. 2015 Apr;
125(4):1763.
PMID: 25831444
No abstract available.